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Whether sunscreen use affects melanoma risk has been widely studied with contradictory results. To answer this question we
performed a systematic review of all published studies, accounting for sources of heterogeneity and bias. We searched for
original articles investigating the sunscreen-melanoma association in humans to February 28, 2018. We then used random-
effects meta-analysis to combine estimates of the association, stratified by study design. Stratified meta-analysis and meta-
regression were used to identify sources of heterogeneity. We included 21,069 melanoma cases from 28 studies published
1979–2018: 23 case–control (11 hospital-based, 12 population-based), 1 ecological, 3 cohort and 1 randomised controlled
trial (RCT). There was marked heterogeneity across study designs and among case–control studies but adjustment for
confounding by sun exposure, sunburns and phenotype systematically moved estimates toward decreased melanoma risk
among sunscreen users. Ever- vs. never-use of sunscreen was inversely associated with melanoma in hospital-based case–
control studies (adjusted odds ratio (OR) = 0.57, 95%confidence interval (CI) 0.37–0.87, pheterogeneity < 0.001), the ecological
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study (rate ratio = 0.48, 95%CI 0.35–0.66), and the RCT (hazard ratio (HR) = 0.49, 95%CI 0.24–1.01). It was not associated in
population-based case–control studies (OR = 1.17, 95%CI 0.90–1.51, pheterogeneity < 0.001) and was positively associated in
the cohort studies (HR = 1.27, 95%CI 1.07–1.51, pheterogeneity = 0.236). The association differed by latitude
(pinteraction = 0.042), region (pinteraction = 0.008), adjustment for naevi/freckling (pinteraction = 0.035), and proportion of never-
sunscreen-users (pinteraction = 0012). Evidence from observational studies on sunscreen use and melanoma risk was weak and
heterogeneous, consistent with the challenges of controlling for innate confounding by indication. The only RCT showed a
protective effect of sunscreen.
What’s new?
Effectiveness of sunscreen in reducing UV-induced skin damage has been proven in experimental studies, but effectiveness in
reducing melanoma in humans remains inconclusive. This is the first meta-analysis to analyze data from four study designs,
stratify hospital- and population-based case–control studies, and include as many as five prospective studies. Evidence from
observational studies on the sunscreen-melanoma association was heterogeneous, consistent with the challenges of
controlling for innate confounding by indication. The only randomized controlled trial showed a protective effect. Public health
recommendations should place greater emphasis on the proper use of sunscreen in conjunction with other means of sun
protection.
Introduction
Cutaneous melanoma is the leading cause of skin cancer
death,1 accounting for 1–2% of all cancer deaths.2,3 In 2015,
melanoma occurred in 351,880 people and resulted in 59,782
deaths worldwide.4
The aetiology of cutaneous melanoma (hereafter termed
melanoma) is a complex interaction of genetic, epigenetic and
environmental risk factors.5,6 Melanoma is mainly caused by
ultraviolet (UV) radiation exposure in sun-sensitive subjects
and it is estimated that more than 85% of melanoma cases in
Europe are attributed to sun exposure.7–10 Genomic sequencing
confirms that the majority of the mutations in melanomas are
caused by UV radiation.11,12 It follows that melanoma is pre-
ventable through reduction of UV exposure, making primary
prevention highly cost-effective.10,13 Use of sunscreen is gener-
ally regarded as a major primary prevention measure alongside
seeking shade, wearing protective clothes, and avoiding
sunbeds,14–17 and is a popular method of sun protection.18
However effectiveness of sunscreen to reduce UV-induced
damage to the skin has been proven only in experimental
studies,19 and evidence of its effectiveness in preventing mela-
noma in humans is inconclusive. Only one randomised con-
trolled trial (RCT) of daily sunscreen application to prevent
skin cancer has been performed, showing a reduced risk of mel-
anoma (hazard ratio = 0.50, p value = 0.051) in those randomly
assigned to daily compared to discretionary sunscreen use.20,21
The compliance to daily sunscreen application was approxi-
mately 75%; the majority of participants in the discretionary
sunscreen group either did not apply sunscreen (38%) or
applied at most once or twice a week (35%).21 All other studies
of sunscreen and melanoma risk have been observational,
mainly case–control, yielding contradictory results.22–40
The main problem with investigating this question with
observational studies is confounding by indication, i.e. sunscreen
users tend to be more susceptible to melanoma and more
exposed to the sun than non-users a priori.41 The contradictory
and heterogeneous results of previous systematic reviews reflect
this problem.42–48 In the current study we aimed to overcome
these known limitations by performing in-depth statistical ana-
lyses, comparing different patterns of sunscreen use and identify-
ing the major sources of heterogeneity. Furthermore we wanted
to update the field with new evidence.
Specifically, we aimed to 1) systematically summarise the
existing literature on sunscreen use and melanoma in humans;
2) investigate the effect of ever- vs. never-use on melanoma
risk; 3) assess the effect of different levels and patterns of sun-
screen use; 4) identify sources of bias and between-study het-
erogeneity; and 5) describe the relationship between site of
sunscreen application and site of melanoma.
Methods
The study protocol of this systematic review (PROSPERO ID:
CRD4201706398049) was written according to PRISMA-
P50,51 and the reporting in this article follows the PRISMA
recommendations.52
Data sources and searches
We searched the electronic databases PubMed (including
Medline), Embase and Cochrane Database of Systematic
Reviews with search terms adapted for each of them
(Supporting Information Appendix I). In addition, we
searched the protocol database PROSPERO to identify rele-
vant ongoing reviews and screen their reference lists. To
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ensure literature saturation we also screened the reference lists
of relevant published reviews.
Study selection
We included all original articles published by 28.02.2018 in
peer-reviewed journals arising from case–control studies, eco-
logical studies (population-level rather than individual-level
observational studies), cohort studies, intervention studies and
clinical trials performed in humans with melanoma as end-
point and sunscreen use as exposure. We only included stud-
ies where the exposure clearly preceded the outcome. We had
no restrictions regarding length of follow-up or language.
Studies on childhood melanoma were included in the qual-
itative synthesis but excluded from the meta-analyses because
UV exposure does not seem to be a risk factor in the aetiology
of melanoma occurring before 15 years of age.53
All records from the literature research were imported into
EndNote (Thomson Reuters, version X8), de-duplicated and
then imported to Microsoft Excel (version 2010) to perform
the selection process. Study selection was performed by two
independent reviewers (CSR and JSS) by first screening titles
and abstracts, then screening full texts. We calculated the pro-
portion of agreement between the two reviewers for each of
the two selection steps. Discrepancies were solved by discus-
sion between the two reviewers. References were excluded
based on the hierarchical exclusion criteria displayed in
Figure 1.
Data extraction and quality assessment
Data were extracted using a data extraction form54 (Supporting
Information Appendix II) after piloting the process with three
studies of different design and publication year. Data extraction
was performed by CSR and the estimates of interest were
double-checked by MBV. Discrepancies were discussed among
a subgroup of the authors until consensus was reached. We
contacted study authors and requested the estimate of interest
if it was not reported but the respective analysis was described.
If necessary, additional articles from the same study were used
to complete data extraction.
For each study we extracted the following estimates on the
association of sunscreen use and melanoma, if reported: a)
ever- vs. never-use of sunscreen from minimally adjusted
model; b) ever- vs. never-use of sunscreen from maximally
adjusted model; c) three-level estimate of sunscreen use from
maximally adjusted models for frequency of use, sun protec-
tion factor (SPF) used and duration of use (Supporting Infor-
mation Table 1). The minimally and maximally adjusted
model was the model with no or only basic adjustment and
the model with most variables included, respectively, in the
original study. We chose the ever- vs. never-use label because
most underlying studies analysed ever- vs. never-use or use vs.
no use of sunscreen based on their questionnaires. In addition,
we extracted bibliographic and demographic information of
the studies, assessment of sunscreen use, and study quality to
identify sources of heterogeneity. Study quality was assessed
based on the Cochrane Handbook‘s tool for assessing risk of
bias54 and the Newcastle-Ottawa Scale (NOS).55 Level of bias
(high, medium, low) was rated by the data extractor (CSR)
after reading the methods part of the study and blinded
toward the study results.
Data synthesis and analysis
All analyses were performed in STATA (StataCorp LP, Release
14.1). In the analysis of ever- vs. never-use of sunscreen we
used the method of Hamling and colleagues to aggregate esti-
mates if more than two categories of sunscreen use were
reported.56 For example, if a study reported an estimate with
three categories of sunscreen use: never, sometimes, and often,
we aggregated ‘sometimes’ and ‘often’ into ever-use. This was
done to make the estimates across studies more comparable.
Without this aggregation we would end up pooling estimates
across studies where some estimates reflected the effect of the
highest sunscreen category vs. no sunscreen use, while others
reflected ever- vs. never use. The same method was used to
change the reference category, if necessary. To investigate
three-level, different patterns and high sunscreen use, we
extracted all estimates with at least three categories on fre-
quency of sunscreen use, SPF used, and duration of use. For
each study, the lowest and highest categories were categorised
as lowest and highest groups, respectively and all intermediate
categories were aggregated.57
We performed random-effects meta-analysis58 stratified
by study design for the minimally and maximally adjusted
estimates of ever- vs. never-use of sunscreen, and for each
three-level variable on sunscreen use, comparing the inter-
mediate to the lowest level and the highest to the lowest
level. Heterogeneity between studies was tested with the Q-
test.59 The I2-index was used to quantify the extent of het-
erogeneity, with I2-values >50%, and > 75% being indicati-
ve of moderate and high heterogeneity, respectively.54
We included one case-cohort study that was analysed
together with the cohort studies because it was conducted
prospectively.
To explore sources of heterogeneity we performed
random-effects meta-analyses stratified by important variables
predefined in the protocol, and univariable random-effects
meta-regression analyses, on the maximally adjusted ever- vs.
never-use estimate. We considered the following variables:
study design; year of the end of the data collection
(1975–1984, 1985–1999, 2000–2012); mean latitude (>42N,
≤42N); region; most frequent melanoma site in the study
population (trunk, head/neck, lower limbs); duration of sun-
screen use (not specified, specified period, lifetime); whether
sunscreen use was assessed in detail or not; level of bias (high,
medium, low); whether or not the estimate of interest was
adjusted for nevi and/or freckles, history of sunburn, or sun
exposure; and, the proportion of participants with blond/red
hair (<30%, ≥30%), blue/green eyes (<50%, ≥50%), history of
Rueegg et al. 3
























































sunburn (<75%, ≥75%), and who never used sunscreen
(<55%, ≥55%). The cut-offs in the proportions were chosen
based on the distribution of the respective characteristic across
the studies. We used tau-squared to estimate the remaining
between-study variance in the meta-regression model by
residual maximum likelihood.58
Figure 1. Flow diagram on inclusion of studies. The figure shows the process of selecting eligible studies for the current review and meta-
analysis. [Color figure can be viewed at wileyonlinelibrary.com]
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Publication bias was investigated by the funnel plot and
Egger’s regression test for the maximally-adjusted ever-never
estimates.60 We used contour-enhanced funnel plots to define
regions of the plot in which a new study would have to be
located to change the statistical significance of the meta-
analysis and thereby assess the robustness of the current
meta-analysis.61
Grading of the evidence
The confidence in the cumulative evidence was assessed using
the Grading of Recommendations Assessment, Development
and Evaluation (GRADE) system.62 GRADE rates the quality of
evidence across the domains risk of bias, consistency, direct-
ness, precision, and publication bias and rates it into one of the
four categories high (further research is very unlikely to change
our confidence in our effect estimate), moderate (further
research is likely to change our confidence in our effect esti-
mate), low (further research is very likely to change our effect
estimate), or very low (our effect estimate is very uncertain).
Results
Study selection
We identified 3,414 records in the three databases Pubmed
(n = 1,054), Embase (n = 2,132), and Cochrane (n = 228), of
which 761 were duplicates and 2,552 were rated as ineligible
on first screening by two reviewers (agreement = 95%; Fig. 1).
Eleven studies were identified through other sources resulting
in the assessment of 112 full-texts, of which 84 (agree-
ment = 89%) were excluded, leaving 28 studies included in
the qualitative synthesis and 27 studies in the meta-analysis
after exclusion of the childhood melanoma study.32
Characteristics of included studies
The 28 articles (11 hospital-based case–control
studies,22,23,31,33–35,37,39,63–65 12 population-based case–control
studies,24–30,32,36,38,40,66 one ecological study,67 three cohort
studies (one of them a case-cohort study),68–70 and one
RCT21) were published between 1979 and 2018, included
208 to 178,155 participants and 33 to 11,535 melanoma cases:
in total, 21,069 melanoma cases, who originated from
Australia (n = 4), Europe (n = 16), Brazil (n = 2) and the
USA (n = 6; Table 1). The median latitude of the study loca-
tions was 43N (range − 30S-65N). On average, 21% of par-
ticipants (range 9–61%) were blond or red-haired, 47% (range
19–86%) blue or green eyed, 48% (range 28–70%) had
freckles, and 55% (range 24–85%) were fair-skinned
(Supporting Information Table 2). Most studies only assessed
sunscreen use or sunscreen use frequency (Table 1). Fourteen
studies defined a timeframe for the sunscreen
use,21,24,25,29,32,35,36,38,40,63,65–68 eight studies assessed the SPF
used,21,35–37,39,40,66,69 three the reapplication,40,65,66 three the
body sites or body coverage,21,36,40 two the product used,35,69 two
the thickness,21,40 and one study the reasons for sunscreen use.36
Methodological quality of included studies
The methodological quality of the case–control studies was very
heterogeneous with 11 hospital-based case–control studies based
on non-representative cases and controls (Supporting Informa-
tion Table 3). The ecological study, cohort studies and RCT ful-
filled almost all of the methodological requirements.54,55
The method and detail of assessment of sunscreen use also
varied greatly between the studies (Table 2); the same was true
for the level of adjustment of the “maximally-adjusted” esti-
mate, though most studies adjusted in some way for UV expo-
sure and some host factors of participants.
Ever sunscreen use and melanoma risk
The forest plot of minimally-adjusted estimates showed substan-
tial heterogeneity both within hospital-based (I2 = 86%,
p < 0.001) and population-based case–control studies (I2 = 80%,
p < 0.001), and between the different study designs (Fig. 2).
The forest plot of maximally-adjusted estimates showed
that adjustment moved most estimates toward a more reduced
risk of melanoma among sunscreen users (Figs. 2 and 3)
though substantial heterogeneity remained (Fig. 3), especially
within case–control studies (I2 = 86%, p < 0.001 for hospital-
based; 81%, p < 0.001 for population-based) but also between
study designs. We found an inverse sunscreen-melanoma
association in hospital-based case–control studies (summary
odds ratio (OR) = 0.57, 95%CI 0.37–0.87), the ecological study
(rate ratio (RR) = 0.48, 95%CI 0.35–0.66), and the RCT (haz-
ard ratio (HR) = 0.49, 95%CI 0.24–1.01). No association was
found on summarising results from population-based case–
control studies (OR = 1.17, 95%CI 0.90–1.51) and a positive
sunscreen-melanoma association was seen on summarising
the three cohort studies (HR = 1.27, 95%CI 1.07–1.51).
Three-level estimates of sunscreen use and melanoma risk
Sixteen studies reported at least a three-level estimate on the
frequency of sunscreen use (never, sometimes, often/
always),22,24–26,29–31,33,35,36,38,40,63,68–70 six studies distinguished
low from high SPF sunscreen use (compared to no
use),35–37,40,66,69 and four studies distinguished short- from
long-term use of sunscreen (compared to no use)24,25,35,36
(Supporting Information Table 4). We did not observe a trend
or U-shaped association comparing the intermediate- and
high-users of sunscreen to the non-users for each of the three-
level estimates (Supporting Information Fig. 1). The summary
estimates comparing sometimes- to never-use were 1.07 (95%
CI 0.80–1.42) in the hospital-based case–control studies, 1.13
(95%CI 0.98–1.30) in the population-based case–control stud-
ies, and 1.38 (95%CI 1.17–162) in the cohort studies. The
summary estimates comparing often/always- to never-use
were 1.01 (95%CI 0.38–2.67) in the hospital-based case–
control studies, 1.01 (95%CI 0.67–1.52) in the population-
based case–control studies, and 1.32 (95%CI 1.10–1.59) in the
cohort studies (Supporting Information Fig. 1A).
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The association between sunscreen use and melanoma from
stratified analyses is presented in Table 3 and Supporting
Information Figure 2. Studies conducted in lower latitudes
showed an inverse association between sunscreen use and
melanoma (summary estimate = 0.64, 95%CI 0.47–0.89 for
studies ≤42N) but there was no association in studies from
higher latitudes (summary estimate = 1.09, 95%CI 0.83–1.44,
pinteraction = 0042). Further statistically significant interactions
were observed between the association of sunscreen use and 1)
the region of the study (pinteraction = 0.008); 2) adjustment for
nevi and/or freckles (with an inverse association only in studies
adjusting; pinteraction = 0.035); and, 3) the proportion of sun-
screen users in the study (with an inverse association of sun-
screen use and melanoma only in studies where ≥55% of
participants never used sunscreen; pinteraction = 0.012). Remain-
ing between-study variance was generally high after all stratifi-
cations (0.131 ≤ tau-squared ≤ 0.492).
Site of sunscreen application and site of melanoma
Two studies21,36 assessed the body site of sunscreen applica-
tion but neither related this to the site of melanoma.
Meta bias and quality of the cumulative evidence
The funnel plot (Supporting Information Fig. 3) shows the effect
estimates from the individual studies against the precision of the
studies (standard error in reversed scale), placing the largest stud-
ies toward the top. In the absence of bias and between-study het-
erogeneity, the plot would have resembled a symmetric inverted
funnel, while our plot showed evidence of asymmetry confirmed
by an Egger’s test for small-study effects (p = 0.010). The funnel
plot with contours of statistical significance (Supporting Informa-
tion Fig. 4) shows which combinations of effect size and standard
error would be required in an additional study, to change or main-
tain the statistical significance of the current summary estimate.
In our meta-analysis, the plot showed that all of the current stud-
ies were lying in the area where future studies (if lying in the same
area) would change the current effect estimate toward a signifi-
cantly positive association between sunscreen use and melanoma
risk (significant effect estimate >1).
The GRADE assessment resulted in an overall very low
quality of evidence from the case–control studies, ecological
study and cohort studies, and in a moderate quality of evi-
dence from the RCT (Supporting Information Table 5).
Discussion
We assessed the sunscreen-melanoma association in 21,068 mela-
noma patients based on 28 studies in this comprehensive system-
atic review. The main body of evidence came from observational
studies with high between-study heterogeneity. We found an
inverse association between sunscreen use and melanoma in
hospital-based case–control studies, the ecological study and the
RCT. There was no association in the population-based case–
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and melanoma in the cohort studies. No clear pattern resulted
when comparing the few studies that reported three-level esti-
mates of sunscreen use regarding frequency of use, SPF of sun-
screen used or duration of use. The association between sunscreen
use and melanoma differed by latitude, region, adjustment for
nevi/freckling, and proportion of never sunscreen users.
Comparison with previous meta-analyses
Our study is the first systematic review and meta-analysis to pre-
sent results from four different study designs, the first to include
five prospective studies, and the first to stratify the case–control
studies into hospital-based and population-based studies. Five
meta-analyses of the association of sunscreen use and melanoma
have been published (in 200243, 200344, 200745, 201546, and
201848). Only Dennis and colleagues (2003)44 aggregated three-
level estimates of sunscreen use into ever- vs. never-use, as we did,
but the final estimate (pooled OR = 1.0, 95%CI 0.8–1.2, from
18 case–control studies) was unadjusted for confounding factors.
Consistent with our findings, they showed that adjustment moved
estimates toward a reduced risk of melanoma in sunscreen users,
by pooling only the nine studies that adjusted for sun sensitivity
(OR = 0.8, 95%CI 0.6–1.0).44 Similar to our approach, Dennis and
colleagues tried to go beyond “ever-use” of sunscreen and pooled
12 case–control studies that reported at least a three-level estimate
on the frequency of sunscreen use (aggregated by ordered regres-
sion models) but found no association.44
Despite high heterogeneity, the other four meta-analyses
pooled results using quite different definitions of sunscreen use
into one estimate (for example always- vs. never-use and ever-
vs. never-use), across very different study designs or different
types of skin cancer, and across estimates from adjusted and
unadjusted models. The earliest meta-analysis (2002)43 included
Figure 2. Forest plot for ever- vs. never-use of sunscreen and melanoma risk, minimally adjusted estimates stratified by study design. The figure shows
the forest plot for melanoma risk comparing ever- vs. never-use of sunscreen for all studies that reported a minimally adjusted estimate, stratified by
study design. The estimates of the case–control studies are reported in odds ratios with 95% confidence intervals (CIs); and, the estimates of the cohort
studies and the RCT as hazard ratios with 95% CIs. Minimal adjustment of some estimates (e.g. age and sex) and exact definition of the estimates is
described in Table 2. Abbreviations: CI, confidence interval; ES, effect size; RCT, randomised controlled trial. * Not ever- vs. never-use of sunscreen; see
Table 2 for the exact definition of the estimate. **Case-cohort study. [Color figure can be viewed at wileyonlinelibrary.com]
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11 case–control studies but pooled only the four registry-based,
resulting in no association (OR = 1.01). Gorham and colleagues
(2007)45 included 17 case–control studies with a pooled OR = 1.2
(95%CI 0.9–1.6). Similar to our review, they found statistically
significant interaction with study latitude. Xie and colleagues
(2015)46 included 21 studies and calculated a summary estimate
of 1.15 (95%CI 0.91–1.44; I2 = 84%, pheterogeneity < 0.001). This
review46 also tried to identify sources of heterogeneity by meta-
regression but found no significant interactions. The most recent
meta-analysis (2018)48 included 30 studies but only 25 were
related to melanoma. They included only two prospective studies
compared to five in our review, included cross-sectional study
designs and calculated a summary estimate despite high hetero-
geneity (summary estimate = 1.08, 95%CI 0.91–1.29, including
melanoma and other skin cancers). It is not possible to directly
compare the aggregated estimates of association from these pre-
vious meta-analyses with our sorted and stratified estimates.
Interpretation of results
When interpreting our results, we needed to account for the dif-
ferent levels of evidence of the study designs included in our
meta-analyses. In the hierarchy of strength of evidence, ecologi-
cal studies are the weakest, and cohort studies and RCTs are the
strongest.71 Our funnel plot showed small-study effects, meaning
that the results in small studies differed from the results in large
studies. We suspect that this funnel plot asymmetry is due to
poor methodological quality in small studies rather than publica-
tion bias.60 This supports the fact that our results need to be
interpreted taking the methodological quality and level of evi-
dence into account as was done in the GRADE assessment.
Figure 3. Forest plot for ever- vs. never-use of sunscreen and melanoma risk, maximally adjusted estimates stratified by study design. The
figure shows the forest plot for melanoma risk comparing ever- vs. never-use of sunscreen for all studies that reported a maximally adjusted
estimate, stratified by study design. The estimates of the case–control studies are reported as odds ratios with 95% confidence intervals
(CIs); the estimates of the cohort studies and the RCT as hazard ratios with 95% CIs; and, the estimate of the ecological study as rate ratio
with 95% CI. Adjustment and exact definition of the estimates is described in Table 2. Abbreviations: CI, confidence interval; ES, effect size;
RCT, randomised controlled trial. *Not ever- vs. never-use of sunscreen; see Table 2 for the exact definition of the estimate. **Case-cohort
study. [Color figure can be viewed at wileyonlinelibrary.com]
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Table 3. Association between sunscreen use and melanoma from stratified analyses
No1 Estimate 95% CI p2 Tau2 3
Study design 0.069 0.221
Hospital-based case–control studies 9 0.57 0.37–0.87
Population-based case–control studies 8 1.17 0.91–1.51
Ecological study 1 0.48 0.35–0.66
Cohort studies 3 1.27 1.07–1.51
Randomised controlled trial 1 0.49 0.24–1.01
Year of the end of data collection 0.3194 0.320
1975–1984 2 1.33 0.93–1.89
1985–1999 10 0.86 0.61–1.21
2000–2012 9 0.82 0.60–1.13
Mean latitude of the study 0.042 0.248
> 42 N 11 1.09 0.83–1.44
≤ 42 N 11 0.64 0.47–0.89
Region of the study 0.008 0.131
Northern Europe 6 1.10 0.78–1.57
Northern America 4 0.89 0.59–1.34
Eastern Europe 1 0.19 0.09–0.42
Western Europe 3 1.61 1.32–1.97
Southern Europe 4 0.55 0.33–0.89
Southern America 2 0.34 0.20–0.59
Australia 2 0.79 0.36–1.74
Most frequent melanoma site 0.825 0.256
Trunk 8 0.72 0.49–1.05
Head/neck 3 0.93 0.57–1.54
Lower limbs 2 0.74 0.29–1.90
Duration of sunscreen use 0.482 0.313
Not specified (general habit) 11 0.94 0.69–1.28
Specified period 10 0.81 0.60–1.10
Lifetime 1 0.34 0.11–1.03
More detailed assessment than “sunscreen yes-no” 0.493 0.319
No (only sunscreen yes-no) 10 0.93 0.66–1.32
Yes (more than sunscreen yes-no) 12 0.80 0.60–1.05
Level of bias 0.884 0.345
High 6 0.76 0.42–1.40
Medium 12 0.84 0.64–1.12
Low 4 1.02 0.73–1.41
Adjusted for nevi/freckling 0.035 0.238
No 8 1.25 0.99–1.56
Yes 14 0.69 0.51–0.92
Adjusted for history of sunburn 0.587 0.323
No 6 0.95 0.63–1.44
Yes 16 0.82 0.64–1.05
Adjusted for sun exposure 0.253 0.295
No 6 0.64 0.38–1.09
Yes 16 0.95 0.77–1.18
Proportion with blond/red hair 0.150 0.411
< 30% 10 0.65 0.44–0.97
≥ 30% 3 1.24 0.80–1.93
(Continues)
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Careful interpretation of the results of the observational
studies is essential because of their multiple methodological
limitations when assessing the sunscreen-melanoma associa-
tion: recall bias (in the case–control studies); ecological fallacy
(in the ecological study, where we do not know whether the
specific individuals who used sunscreen were those with lower
incidence of melanoma because the association was measured
at the population level); difficulty in meaningfully assessing
sunscreen use by ad hoc questionnaires; and, by far the most
concerning, residual confounding since the determinants of
sunscreen use and melanoma (susceptibility to sunburn and
high sun exposure) are almost inseparable in observational
studies.41 Furthermore, in their large population-based cohort
study,69 Ghiasvand and colleagues found significant differences
between sunscreen users and non-users in regard to phenotype
and sun exposure. Our review highlights the profound influence
of residual confounding by showing that increasing adjustment
systematically moved effect estimates toward a more reduced
risk of melanoma among sunscreen users. The problems incor-
porated in observational studies have also led to an overall very
low quality of evidence in the GRADE rating.72 To overcome
this problem we suggest performing cohort studies that also
explore reasons for sunscreen use and non-use, and how sun-
screen users’ behaviour differs from that of non-users,73 or ana-
lysing cohort studies using newer statistical methods (for
example inverse probability weighting of using sunscreen) that
can adjust for confounding by indication and mimic an RCT
design.74 In observational studies, “treatment selection” (sun-
screen use in our case) is often influenced by subject characteris-
tics. As a result, baseline characteristics of subjects using
sunscreen differ systematically from those not using sunscreen.
A propensity score such as inverse probability weights is the
probability of using sunscreen conditional on observed baseline
characteristics. Applying such weights allows one to analyse an
observational (nonrandomized) study so that it mimics an RCT
by balancing the distribution of observed baseline covariates
between sunscreen users and non-users.75
The strongest existing evidence comes from the one RCT,
as suggested by the pyramid of evidence.76 The RCT was
performed in an Australian population with high year-round
sun exposure and skin cancer awareness.21,77 There is there-
fore a need for additional high-quality, large RCTs in coun-
tries of higher latitude, but these are highly unlikely to be
conducted because of ethical constraints (vulnerable study
participants cannot be denied regular use of sunscreen) and
the need to enrol extremely large numbers of participants in
order to prospectively assess the rare outcome of mela-
noma.19 However, future RCTs could examine intermediate
endpoints (biomarkers, genetic mutations) to improve the
evidence-base for sunscreen use.19
Because of the imprecise definition of ever- vs. never-use of
sunscreen and highly variable assessment of sunscreen use
across studies, we compared the studies reporting at least
three-levels and different patterns of sunscreen use. Unfortu-
nately very few studies reported such estimates, and therefore
we could not provide evidence about what pattern of use
would be most effective and whether there is a discernible
trend with increasing frequency of sunscreen use. We gener-
ally observed that very few studies assessed sunscreen use
behaviour in depth such as exploring thickness of sunscreen
applied, re-application or proportion of body covered with
sunscreen. Such information would be crucial to assess in
future research in relation to melanoma risk since we know
that most people do not apply sunscreen properly.78,79
Of further concern is the high heterogeneity between studies
that could not be fully explained by the variables we investigated in
the meta-regression analysis (see also heterogeneity between study
participants in Supporting Information Table 2).We found amore
protective effect of sunscreens in lower latitudes and Southern
countries. This might be due to sun exposure being more
Table 3. Association between sunscreen use and melanoma from stratified analyses (Continued)
No1 Estimate 95% CI p2 Tau2 3
Proportion with blue/green eyes 0.326 0.492
< 50% 7 0.57 0.35–0.93
≥ 50% 4 0.93 0.48–1.79
Proportion with history of sunburn 0.406 0.429
< 75% 6 0.62 0.33–1.15
≥ 75% 7 0.98 0.72–1.31
Proportion of never5 sunscreen user 0.012 0.164
< 55% 13 1.03 0.83–1.28
≥ 55% 4 0.42 0.32–0.55
Abbreviations: CI, confidence interval; No, number; p, p value.
1Number of studies in each group.
2p Value for interaction from univariable meta-regression model.
3Remaining between-study variance estimated by residual maximum likelihood.
4p Value for trend.
5A few studies included rare sunscreen users in the “never user” category. See Table 2 for the exact definition of the sunscreen variable.
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homogeneous in these studies (everybody is exposed to some
degree) and to sunscreen use being regarded as a routine preven-
tive measure rather than being regarded as a means to prolong sun
exposure by some at higher latitudes.80,81 It would therefore be
important to distinguish between studies where sunscreen was
used for intentional sun exposure and tan acquisition versus for
protection from sun damage. This was not possible with currently
available evidence. Also, people from lower and higher latitude
might differ in their interpretation of frequencies of sunscreen use.
For example higher latitude participants might consider “often”
using sunscreenmeans applying on sunny days, whereas lower lat-
itude participants may think of “often” using sunscreen as daily
application.
We further found an inverse association between sunscreen
use and melanoma in studies where the estimate was adjusted for
number of naevi and/or freckling, while no association was found
in studies without such adjustment. This might be due to the fact
that number of naevi/freckling are especially important predictors
of melanoma,82 and self-reported assessment of number of naevi/
freckling as confounding factor might be more valid than other
factors (e.g. sun exposure or sunburns long time ago).83,84 We
found an inverse association of sunscreen use and melanoma in
studies with a high proportion of never sunscreen users. This
makes sense because of a better contrast between sunscreen users
and non-users, revealing the effect of sunscreen in populations
where the majority is not using it.
Strengths and limitations
This systematic review has several strengths. Compared to previ-
ous reviews, it adds several new studies and study designs, includ-
ing three large cohort studies, and performs in-depth statistical
analyses. We have extracted a variety of descriptive variables to
identify sources of heterogeneity. To make the sunscreen variable
as comparable as possible between studies, we attempted to aggre-
gate or transform the estimates into ever- vs. never-use of sun-
screen in order to combine the studies, but this inherited the
weakness that the sunscreen measure was very broad, further
obscuring any true effect of sunscreen.
Other limitations include the relatively low number of eligible
studies, especially intervention studies and studies reporting three-
level estimates on sunscreen use, the difference in study designs,
and the between-study heterogeneity. Because of the high heteroge-
neity we could not calculate an overall summary estimate. Due to
the limited number of studies we could not perform multivariable
meta-regression analysis, and were forced to collapse the meta-
regression and stratified meta-analysis over the different study
designs. Also, we could not identify enough studies to answer our
last research question on a possible relationship between body sites
of sunscreen application and of melanoma. Furthermore, we used
the label ever- vs. never-use because never or no use were the terms
mostly used in the original studies included in the meta-analysis.
This might be somewhat misleading as the never-users probably
include some who used sunscreen rarely.
Conclusion
We found overall weak and heterogeneous published evidence for
an association between sunscreen use and melanoma. Observa-
tional studies showed an inverse association in hospital-based
case–control studies and the ecological study, no association in
population-based case–control studies and a positive association in
the three cohort studies. A protective effect of sunscreen was found
in the only RCT performed. We therefore advocate for studies
examining intermediate (biological) endpoints to be used in high-
quality RCTs. The effectiveness of sunscreen to reduce UV radia-
tion to the skin has been proven after acute exposure in human
studies and in experimental studies.19 In our review, this translated
into a reducedmelanoma risk in the long-term for only some stud-
ies and we attribute this to residual confounding of observational
studies and the misuse of sunscreen to increase rather than
decrease sun exposure in some high latitude populations. Public
health recommendations should place greater emphasis on the
proper use of sunscreen (for sun protection vs. to prolong time in
the sun) in conjunction with other means of sun protection.
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